About Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ)
Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. The Company's activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine. The Company has completed Phase I safety studies of its product candidate in Europe. In pre-clinical testing, anatabine demonstrates anti-inflammatory activity in a range of in vitro and in vivo assays.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RCPIQ
CUSIPN/A
Phone844-727-0727
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares170,450,000
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Frequently Asked Questions
What is Rock Creek Pharmaceuticals' stock symbol?
Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ."
How were Rock Creek Pharmaceuticals' earnings last quarter?
Rock Creek Pharmaceuticals Inc (OTCMKTS:RCPIQ) released its quarterly earnings data on Monday, November, 11th. The company reported ($0.02) EPS for the quarter. The company earned $2.26 million during the quarter, compared to the consensus estimate of $1.70 million. View Rock Creek Pharmaceuticals' Earnings History.
Who are some of Rock Creek Pharmaceuticals' key competitors?
Some companies that are related to Rock Creek Pharmaceuticals include Actelion (ALIOF), Stada Arzneimittel (STDAF), USANA Health Sciences (USNA), ChromaDex (CDXC), Foamix Pharmaceuticals (FOMX), MediWound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), PharmaCyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), Glg Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), Nutra Pharma (NPHC) and FitLife Brands (FTLF).
Who are Rock Creek Pharmaceuticals' key executives?
Rock Creek Pharmaceuticals' management team includes the folowing people:
- Michael John Mullan Ph.D. M.D., Chairman of the Board, Office of President, Chief Executive Officer (Age 59)
- William L. McMahon, Chief Financial Officer (Age 64)
- Theodore Jenkins, Secretary, Vice President - Corporate Strategy & Development
- Lee M. Canaan, Independent Director (Age 59)
- Robert W. Scannell, Independent Director (Age 57)
Has Rock Creek Pharmaceuticals been receiving favorable news coverage?
News coverage about RCPIQ stock has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rock Creek Pharmaceuticals earned a daily sentiment score of 0.10 on Accern's scale. They also assigned news articles about the company an impact score of 44.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Rock Creek Pharmaceuticals?
Shares of RCPIQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rock Creek Pharmaceuticals' stock price today?
One share of RCPIQ stock can currently be purchased for approximately $0.0008.
How big of a company is Rock Creek Pharmaceuticals?
Rock Creek Pharmaceuticals has a market capitalization of $140,000.00.
How can I contact Rock Creek Pharmaceuticals?
Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The company can be reached via phone at 844-727-0727 or via email at [email protected]
MarketBeat Community Rating for Rock Creek Pharmaceuticals (RCPIQ)
MarketBeat's community ratings are surveys of what our community members think about Rock Creek Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCPIQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCPIQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/25/2016 forward)
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Earnings History and Estimates Chart
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/10/2016 | Q2 2016 | | ($0.04) | | | View | N/A |  |
| 5/16/2016 | Q1 2016 | | ($0.22) | | | View | N/A | |
| 11/9/2015 | Q3 2015 | | ($0.26) | | | View | N/A | |
| 8/10/2015 | Q2 2015 | | ($0.09) | | | View | N/A | |
| 5/12/2015 | Q1 2015 | | ($0.03) | | | View | N/A | |
| 11/10/2014 | Q3 2014 | | ($0.75) | | | View | N/A | |
| 8/11/2014 | Q2 2014 | | ($1.75) | | $0.72 million | View | N/A | |
| 5/12/2014 | Q1 2014 | | ($1.50) | | $1.12 million | View | N/A | |
| 11/11/2013 | Q3 | | ($0.02) | $1.70 million | $2.26 million | View | N/A | |
| 8/9/2013 | Q2 2013 | | ($1.25) | | $2.52 million | View | N/A | |
| 5/10/2013 | Q1 2013 | | ($1.25) | $2.10 million | $2.51 million | View | N/A | |
| 3/18/2013 | Q4 2012 | ($0.75) | ($1.25) | | | View | N/A | |
| 11/9/2012 | Q3 2012 | ($0.75) | ($1.25) | | | View | N/A | |
| 8/9/2012 | Q2 2012 | ($0.50) | ($1.38) | | | View | N/A | |
| 5/10/2012 | Q1 2012 | | ($0.93) | | | View | N/A | |
| 3/15/2012 | Q4 2011 | ($1.00) | ($3.75) | | | View | N/A | |
| 11/9/2011 | Q3 2011 | ($1.00) | ($1.23) | | | View | N/A | |
| 8/9/2011 | Q2 2011 | ($1.75) | ($0.93) | | | View | N/A | |
| 5/11/2011 | Q1 2011 | ($0.75) | ($1.25) | | | View | N/A | |
| 3/16/2011 | Q4 2010 | | ($1.00) | | | View | N/A | |
| 11/10/2010 | Q3 2010 | ($1.00) | ($1.00) | | | View | N/A | |
| 5/10/2010 | Q1 2010 | ($0.75) | ($1.13) | | | View | N/A | |
| 11/9/2009 | Q3 2009 | | ($1.25) | | | View | N/A | |
| 8/10/2009 | Q2 2009 | | ($1.73) | | | View | N/A | |
| 5/11/2009 | Q1 2009 | | ($1.38) | | | View | N/A | |
| 3/16/2009 | Q4 2008 | | ($0.25) | | | View | N/A | |
| 11/10/2008 | Q3 2008 | | ($1.20) | | | View | N/A | |
| 8/8/2008 | Q2 2008 | | ($1.75) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.89%
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/30/2016 | Robert Scannell | Director | Buy | 285,714 | $0.35 | $99,999.90 | | |
(Data available from 1/1/2013 forward)
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) News Headlines
| Source: |
|
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
